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Kefir is a complex fermented dairy product created through the symbiotic fermentation
of milk by lactic acid bacteria and yeasts contained within an exopolysaccharide
and protein complex called a kefir grain. As with other fermented dairy products,
kefir has been associated with a range of health benefits such as cholesterol
metabolism and angiotensin-converting enzyme (ACE) inhibition, antimicrobial activity,
tumor suppression, increased speed of wound healing, and modulation of the immune
system including the alleviation of allergy and asthma. These reports have led to
increased interest in kefir as a focus of research and as a potential probiotic-containing
product. Here, we review those studies with a particular emphasis on the microbial
composition and the health benefits of the product, as well as discussing the further
development of kefir as an important probiotic product.
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INTRODUCTION
Fermented dairy products have long been associated with the ability to confer health benefits in
those who regularly consume them, with Ellie Metchnikoff first theorizing that their impact on
the bacterial microbiota in the gut contributed to health and long life (Metchnikoff, 1908). Indeed
many reportedly probiotic-containing foods come in the form of fermented milk products, such as
yogurt, koumis, and kefir, many of which have been consumed for 100s of years (Tamime, 2002;
Parvez et al., 2006). Probiotics are live microorganisms which, when administered in adequate
amounts, confer a health benefit on the host (Hill et al., 2014). As is the case with the fermented
dairy products referred to above, probiotics are consumed in foods containing these organisms in
sufficiently large quantities to pass safely to the gastrointestinal tract but can also come in the form
of supplements consisting of live organisms such as pills.
Although not as widely popular as other fermented dairy products, such as yogurt and cheese,
kefir has been consumed and associated with health benefits for 100s of years; originally by
communities in the Caucasian mountains. The beverage itself typically has a slightly viscous texture
with tart and acidic flavor, low levels of alcohol, and in some cases slight carbonation. Kefir is
traditionally made with cow’s milk but it can be made with milk from other sources such as goat,
sheep, buffalo, or soy milk (Ismail et al., 1983; Motaghi et al., 1997; Wszolek et al., 2001; Liu et al.,
2006a). One of the features that distinguish kefir from many other fermented dairy products is the
requirement for the presence of a kefir grain in fermentation and the presence and importance
of a large population of yeasts (Tamime, 2002; Tamang et al., 2016). The aforementioned kefir
grains are microbially derived protein and polysaccharide matrices that contain a community of
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bacterial and fungal species that are essential to kefir fermentation
(Garrote et al., 2001; Marsh et al., 2013). Traditionally,
fermentation was initiated through the addition of kefir grains,
which originally formed during the fermentation of milk, to
unfermented milk in a sheep or goat skin bag (Motaghi et al.,
1997). Commercial, industrial-scale production rarely utilizes
kefir grains for fermentation, but rather uses starter cultures of
microbes that have been isolated from kefir or kefir grains in
order to provide more consistent products (Assadi et al., 2000).
While this industrially produced kefir may have health benefits
of its own, research examining such benefits has either not been
performed or is not published. Thus, any kefir referred to in this
review has been produced in a traditional manner using kefir
grains or grain fermented milk as the inoculum. In addition to the
microbial population present in kefir, these beverages typically
also contain an abundance of fermentation products such as
organic acids and multiple volatile flavor compounds including
ethanol, acetaldehyde, and diacetyl (Güzel-Seydim et al., 2000).
As part of the fermentation process, an exopolysaccharide unique
to kefir, kefiran, is produced. Kefiran makes up a large proportion
of the kefir grain itself and is also found dissolved in the liquid
phase, where it contributes to the rheology and texture of the
finished product (La Rivière et al., 1967; Frengova et al., 2002;
Rimada and Abraham, 2006).
In this review we will discuss the many health promoting
effects that have been attributed to kefir, including tumor
suppression and prevention, gastrointestinal immunity and
allergy, wound healing, cholesterol assimilation and ACE
inhibition, its antimicrobial properties, and the ability of kefir
to modify the composition and activity of the gut microbiota
(Figure 1).
BACTERIAL AND FUNGAL
POPULATIONS OF KEFIR
Bacterial Populations
Since the first established use, 100s of years ago, the propagation
of kefir has been performed by transferring kefir grains from
one batch to fresh milk and incubating at ambient temperature.
Over this period there has been substantial opportunity for
the microbial component of kefir grains to evolve and diverge,
resulting in the addition or loss of bacteria and yeasts as well
as the addition and loss of genes. The bacterial genera most
commonly found in kefir using culture dependent techniques
are Lactobacillus, Lactococcus, Streptococcus, and Leuconostoc
(Simova et al., 2002; Witthuhn et al., 2004; Chen et al., 2008).
These genera tend to dominate the population present in
both the kefir grain and milk, with Lactococcus lactis subsp.
lactis, Streptococcus thermophilus, Lactobacillus delbrueckii subsp.
bulgaricus, Lactobacillus helveticus, Lactobacillus casei subsp.
pseudoplantarum, Lactobacillus kefiri, Lactobacillus kefir, and
Lactobacillus brevis accounting for between 37 and 90% of
the total microbial community present (Simova et al., 2002;
Witthuhn et al., 2004; Miguel et al., 2010). While these
species commonly make up the majority of the microbial
population present in kefir grains, some grains are dominated
by yeast species or other bacterial species such as Leuconostoc
mesenteroides (Witthuhn et al., 2004). The proportions of species
can also differ between the grain and milk (Figure 2). For
example, L. lactis subsp. lactis, and S. thermophilus levels are
generally much greater in the fermented kefir than in the kefir
grains. The levels of these species increase further in kefir made
from kefir as an inoculum. Indeed, the total increase observed
FIGURE 1 | Major health benefits associated with kefir and the fractions or parts of kefir responsible for these benefits.
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FIGURE 2 | Representation of bacterial population changes from kefir grain (A) to fermented milk (B) and fungal population changes from kefir grain
(A) to fermented milk (B). Figure generated using data from Marsh et al. (2013).
has been as much as 30% in some cases (Simova et al., 2002).
The reason for this increase during fermentation in the milk
may be due to an increase in temperature created by the active
fermentation or simply due to where these bacteria reside in the
kefir grain, as organisms such as Lactobacillus may tend to reside
deeper within the kefir grain, thus making it harder for them to
escape in to the milk.
In agreement with the majority of culture base studies,
investigation of the microbial composition of diverse kefir grains
using culture independent techniques found that the overall
bacterial populations were for the most part dominated by
Firmicutes and Proteobacteria, and kefir milk contained a much
higher level of representatives of the Streptococcaceae than any
other family, (Dobson et al., 2011; Marsh et al., 2013). Based
on high-throughput sequencing of 16S genes present in kefir
grains and milk, it was established that kefir grains typically have
1 (Lactobacillus) or 2 (Lactobacillus and Acetobacter) dominant
bacterial genera (Marsh et al., 2013; Nalbantoglu et al., 2014;
Garofalo et al., 2015; Korsak et al., 2015). The most common
species of Lactobacillus have been L. kefiranofaciens, L. kefiri, and
L. parakefiri (Dobson et al., 2011; Leite et al., 2012; Hamet et al.,
2013; Vardjan et al., 2013; Nalbantoglu et al., 2014; Garofalo et al.,
2015; Korsak et al., 2015). There are many other genera present
in these grains; however, they typically represent less than 10% of
the community (Leite et al., 2012; Marsh et al., 2013; Nalbantoglu
et al., 2014; Garofalo et al., 2015). When milk fermented by
these same grains was examined, the relative abundance of
the genera present vary much more than in the grain, with
Leuconostoc, Lactococcus, Lactobacillus, and Acetobacter being
the most abundant (Marsh et al., 2013; Korsak et al., 2015). As has
previously been stated, bacteria found at lower abundance in the
kefir grain can become dominant, as species such as Lactococcus
are minimally represented in kefir grain, but regularly become the
most abundant genus present in the kefir milk (Dobson et al.,
2011; Marsh et al., 2013). This observation is consistent with
past culture based work, where Lactococcus was found to increase
through the fermentation process (Simova et al., 2002). At the
species level, high throughput 16S analysis showed the number
of OTUs vary from 24 to 56 in the kefir grain, and 22 to 61 in
kefir milk, i.e., much higher than what has been observed utilizing
culture dependent techniques (Marsh et al., 2013). These findings
highlight the need for future studies to examine the kefir grain
and fermented milk rather than the previous tendency to focus
solely on the population of the grain.
With respect to the non-lactic acid bacteria (LAB) that have
been associated with kefir, it is notable that culture independent
methods have revealed Acetobacter as one of the dominant
genera present in grains. This is of interest as Acetobacter is not
commonly isolated from kefir via culture dependent techniques
and, indeed, has been described as a non-essential contaminant
of kefir (Angulo et al., 1993; Pintado et al., 1996; Rea et al.,
1996; Witthuhn et al., 2004). While there are some studies
that have found acetic acid bacteria in large quantities in kefir
grains (Rea et al., 1996), many rely on isolation media that is
not optimal for growth of acetic acid bacteria without further
tests in order to gather an accurate identification (Witthuhn
et al., 2005). Bifidobacterium species have also been identified
through culture independent studies, however, Bifidobacterium
has not been found in any culture based studies of the kefir
microbiota (Dobson et al., 2011; Tas¸ et al., 2012; Marsh et al.,
2013). Table 1 contains a complete list of bacterial species found
in both culture dependent and culture independent studies, while
Figure 3 provides a breakdown of the distribution of species
found in these studies.
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TABLE 1 | List of bacterial and fungal species found in kefir grains and milk using both culture dependent and culture independent techniques.
Microbial species Reference
Lactobacillus
Lactobacillus kefir Angulo et al., 1993; Pintado et al., 1996; Garrote et al., 2001; Santos et al., 2003; Mainville et al., 2006; Miguel et al., 2010
Lactobacillus kefiranofaciens Santos et al., 2003; Mainville et al., 2006; Chen et al., 2008; Dobson et al., 2011; Hamet et al., 2013; Vardjan et al., 2013;
Nalbantoglu et al., 2014; Garofalo et al., 2015; Korsak et al., 2015; Zanirati et al., 2015
Lactobacillus delbrueckii Simova et al., 2002; Santos et al., 2003; Witthuhn et al., 2004; Nalbantoglu et al., 2014
Lactobacillus helveticus Simova et al., 2002; Chen et al., 2008; Dobson et al., 2011; Nalbantoglu et al., 2014
Lactobacillus casei Angulo et al., 1993; Simova et al., 2002; Nalbantoglu et al., 2014; Zanirati et al., 2015
Lactobacillus kefiri Chen et al., 2008; Miguel et al., 2010; Dobson et al., 2011; Hamet et al., 2013; Vardjan et al., 2013; Nalbantoglu et al., 2014;
Garofalo et al., 2015; Korsak et al., 2015; Zanirati et al., 2015
Lactobacillus brevis Angulo et al., 1993; Simova et al., 2002; Santos et al., 2003; Witthuhn et al., 2005; Nalbantoglu et al., 2014
Lactobacillus paracasei Santos et al., 2003; Miguel et al., 2010; Hamet et al., 2013; Nalbantoglu et al., 2014
Lactobacillus parakefir Takizawa et al., 1994; Garrote et al., 2001; Miguel et al., 2010
Lactobacillus plantarum Garrote et al., 2001; Santos et al., 2003; Miguel et al., 2010; Nalbantoglu et al., 2014
Lactobacillus satsumensis Miguel et al., 2010; Zanirati et al., 2015
Lactobacillus curvatis Witthuhn et al., 2004
Lactobacillus fermentum Angulo et al., 1993; Witthuhn et al., 2004, 2005
Lactobacillus viridescens Angulo et al., 1993
Lactobacillus acidophilus Angulo et al., 1993; Santos et al., 2003; Dobson et al., 2011; Nalbantoglu et al., 2014
Lactobacillus gasseri Angulo et al., 1993; Nalbantoglu et al., 2014
Lactobacillus kefirgranum Takizawa et al., 1994; Vardjan et al., 2013
Lactobacillus parakefiri Dobson et al., 2011; Hamet et al., 2013; Vardjan et al., 2013; Nalbantoglu et al., 2014; Korsak et al., 2015
Lactobacillus parabuchneri Dobson et al., 2011; Nalbantoglu et al., 2014
Lactobacillus garvieae Dobson et al., 2011
Lactobacillus buchneri Nalbantoglu et al., 2014; Garofalo et al., 2015
Lactobacillus sunkii Nalbantoglu et al., 2014; Garofalo et al., 2015
Lactobacillus crispatus Nalbantoglu et al., 2014; Garofalo et al., 2015
Lactobacillus otakiensis Nalbantoglu et al., 2014; Garofalo et al., 2015
Lactobacillus instestinalis Garofalo et al., 2015
Lactobacillus amylovorus, L. pentosus,
L. salivarius, L. johnsonii, L. rhamnosus,
L. rossiae, L. sakei, L. reuteri,
L. kalixensis, L. rapi, L. diolivorans,
L. parafarraginis,
L. gallinarum, Pediococcus claussenii,
P. damnosus, P. halophilus,
P. pentosaceus, P. lolii
Nalbantoglu et al., 2014
Lactococcus/Streptococcus
Lactococcus lactis subsp. lactis Angulo et al., 1993; Pintado et al., 1996; Garrote et al., 2001; Simova et al., 2002; Witthuhn et al., 2004, 2005;
Yüksekdag˘ et al., 2004; Mainville et al., 2006; Chen et al., 2008; Garofalo et al., 2015; Zanirati et al., 2015
Lactococcus lactis subsp. cremoris Yüksekdag˘ et al., 2004; Mainville et al., 2006; Korsak et al., 2015
Lactococcus lactis subsp. lactis biovar
diacetylactis
Garrote et al., 2001
Lactococcus garvieae Nalbantoglu et al., 2014
Streptococcus salivarius subsp.
thermophilus
Angulo et al., 1993
Streptococcous thermophilus Simova et al., 2002; Yüksekdag˘ et al., 2004; Mainville et al., 2006; Garofalo et al., 2015
Streptococcus durans Yüksekdag˘ et al., 2004
Leuconostoc/Oenococcus
Leuconostoc spp. Angulo et al., 1993
Leuconostoc mesenteroides subsp.
mesenteroides
Witthuhn et al., 2004; Mainville et al., 2006
Leuconostoc mesenteroides subsp.
cremoris
Witthuhn et al., 2005; Mainville et al., 2006
Leuconostoc mesenteroides Simova et al., 2002; Chen et al., 2008; Nalbantoglu et al., 2014; Korsak et al., 2015; Zanirati et al., 2015
Leuconostoc pseudomesenteroides Mainville et al., 2006
Oenococcus oeni Nalbantoglu et al., 2014
(Continued)
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TABLE 1 | Continued
Microbial species Reference
Acetobacter
Acetobacter spp. Angulo et al., 1993; Garrote et al., 2001; Marsh et al., 2013; Garofalo et al., 2015
Acetobacter sicerae Li et al., 2014
Acetobacter orientalis, Acetobacter
lovaniensis
Korsak et al., 2015
Bifidobacterium
Bifidobacterium spp. Marsh et al., 2013
Bifidobacterium breve, B. choerinum,
B. longum, B. pseudolongum
Dobson et al., 2011
Yeast and fungal species
Zygosaccharomyces spp. Witthuhn et al., 2004, 2005
Candida kefyr Angulo et al., 1993; Marquina et al., 2002; Witthuhn et al., 2004
Candida lipolytica Witthuhn et al., 2004
Saccharomyces cerevisiae Angulo et al., 1993; Marquina et al., 2002; Simova et al., 2002; Witthuhn et al., 2004; Latorre-García et al., 2007; Marsh et al.,
2013; Vardjan et al., 2013; Diosma et al., 2014; Garofalo et al., 2015
Candida holmii Angulo et al., 1993; Witthuhn et al., 2004; Latorre-García et al., 2007
Torulaspora delbrueckii Angulo et al., 1993; Vardjan et al., 2013
Saccharomyces unisporus Angulo et al., 1993; Pintado et al., 1996; Marquina et al., 2002; Latorre-García et al., 2007; Wang et al., 2008; Marsh et al.,
2013; Vardjan et al., 2013; Diosma et al., 2014; Garofalo et al., 2015
Candida friedrichii Angulo et al., 1993
Kluyveromyces lactis Angulo et al., 1993; Marquina et al., 2002; Latorre-García et al., 2007
Pichia fermentans Angulo et al., 1993; Wang et al., 2008; Marsh et al., 2013
Issatchenkia orientalis Latorre-García et al., 2007; Marsh et al., 2013; Diosma et al., 2014
Kluyveromyces marxianus Marquina et al., 2002; Wang et al., 2008; Marsh et al., 2013; Vardjan et al., 2013; Diosma et al., 2014; Korsak et al., 2015
Saccharomyces turicensis Wang et al., 2008; Garofalo et al., 2015
Dekkera anomala Marsh et al., 2013; Garofalo et al., 2015
Kazachstania exigua Vardjan et al., 2013; Garofalo et al., 2015; Korsak et al., 2015
Naumovozyma spp. Korsak et al., 2015
Cryptococcus humicolus,
Geotricum candidum
Witthuhn et al., 2005
Kazachstania servazzii, Ka. solicola,
Ka. aerobia, Saccharomyces
cariocanus
Garofalo et al., 2015
Kluyveromyces marxianus var. lactis,
Candida inconspicua, C. maris
Simova et al., 2002
Saccharomyces humaticus, Candida
sake, Yarrowia lipolytica, Dipodascus
capitatus, Trichosporon coremiiforme
Latorre-García et al., 2007
Ganoderma lucidum, Dioszegia
hungarica, Heterbasidion annosum,
Peziza campestris, Cyberlindnera
jadinii, Malassezia pachydermatis,
Teratosphaeria knoxdaviesii,
Cryptococcus sp. Vega 039,
Microdochium nivale, Wallemia sebi,
Zygosaccharomyces lentus, Eurotium
amsteldami, Dekkera bruxellensis,
Kazachstania barnettii, Naumovozyma
castelli, Davidiella tassiana, Penicillium
sp. Vega 347
Marsh et al., 2013
Yeast Populations
In addition to the large and variable bacterial population in
kefir grains, there is an abundant yeast population that exists
in a symbiotic relationship with the bacteria (Simova et al.,
2002; Witthuhn et al., 2004; Marsh et al., 2013). Three genera
of yeasts are commonly isolated from kefir grains or milk, and
typically make up the majority of the total yeast population;
Saccharomyces, Kluyveromyces, and Candida (Angulo et al.,
1993; Marquina et al., 2002; Simova et al., 2002; Diosma et al.,
2014).
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FIGURE 3 | The number of times an individual species has been identified in kefir expressed as a percentage of the total number of species in the
same genera. CD, culture dependent identification; CI, culture independent identification; N values represent the total number of times a species within the genus
has been identified.
Many different species of Saccharomyces have been isolated
from kefir, however, S. cerevisiae and S. unisporus are the most
common and present in many varieties (Angulo et al., 1993;
Marquina et al., 2002; Latorre-García et al., 2007; Diosma et al.,
2014). Kluyveromyces make up the majority or entirety of the
lactose utilizing yeast population, with K. marxianus and K. lactis
being the two most common species (Simova et al., 2002; Latorre-
García et al., 2007; Diosma et al., 2014). The Candida population
is made up of a wide range of species with C. holmii and
C. kefyr being the most prevalent (Angulo et al., 1993; Marquina
et al., 2002). Outside of these three genera, only Pichia has
been identified with any regularity and in each case the species
was identified as Pichia fermentans (Angulo et al., 1993; Wang
et al., 2008). As fermentation progresses the proportions of
some yeast species change with non-lactose fermenting yeasts,
such as Saccharomyces, decreasing, whereas lactose utilizing
K. marxianus and K. lactis show a similar distribution between
grain and kefir (Simova et al., 2002).
Unlike the bacterial population in kefir grain, the yeast
component of the grain fluctuates considerably between
grains when analyzed using culture independent techniques.
Despite this, a small number of yeasts such as Kazachstania,
Kluyveromyces, and Naumovozyma tend to be the dominant
genera present in both the grain and fermented milk (Zhou et al.,
2009; Marsh et al., 2013; Vardjan et al., 2013; Garofalo et al., 2015;
Korsak et al., 2015). Of these main genera, only Naumovozyma
has not been isolated in culture based studies. Kazachstania
unispora, the species of Kazachstania present is also known as
Saccharomyces unisporus (Marsh et al., 2013). Sequencing based
approaches have also identified over a dozen yeast species that
had not previously been associated with kefir, such as Dekkera
anomala, Issatchenkia orientalis, and Pichia fermentans, and
have even shown that, in some grains, the yeast population is
dominated by a mix of these other species (Marsh et al., 2013;
Garofalo et al., 2015). Table 1 contains a complete list of yeast
species found in culture dependent and culture independent
studies.
Culture Dependent vs. Culture
Independent Methods
As expected, sequencing based methods often identify organisms
that are not readily isolated by traditional culture based methods.
This may be due to the presence of these organisms in extremely
low numbers, or some of these organisms may be unable to grow
on traditional media due to the complex symbiotic relationships
present in kefir. Indeed, this may account for why certain
Lactobacillus species have only been identified in sequencing
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based studies (Dobson et al., 2011). For example L. kefiranofaciens
has not consistently been isolated in culture based methods but is
regularly identified as a major part of the Lactobacillus population
present in kefir when culture independent methods are used
which may be due to the more strict anaerobic nature of this
species when compared to other Lactobacillus species (Wang
et al., 2012). While sequencing based methods have proven to
be very valuable for identifying difficult to culture organisms,
high throughput sequencing of 16S amplicons are limited
with respect to their ability to consistently identify organisms
at the species level (Marsh et al., 2013). Additionally, with
metagenomic analyses there is the possibility that population
dynamics may be skewed if there are dead cells present. While
large numbers of dead cells from one species may indicate the
importance of that species to kefir, the detection of these dead
cells can still be problematic at later times during fermentation
as they would not be actively involved in the community at
these time points. Culture based methods remain essential as
they allow organisms to be phenotypically tested. Regardless,
the advent of sequence based technologies has increased the
knowledge of which organisms are present in kefir grains and
fermented milk and will allow for the development of new
strategies to facilitate the isolation of organisms previously
overlooked.
CHOLESTEROL METABOLISM AND ACE
INHIBITION
Due to the highly complex microbiota of kefir, there is a
multitude of organisms and metabolic products present in the
fermented milk. This combination of live microbial organisms
and metabolites contributes to a wide range of effects attributed
to kefir many of which are health benefits. Cardiovascular disease
(CVD) is one of the leading causes of death in the western
world, with high levels of serum cholesterol being a major
risk factor for the disease. Diet can play a major role in the
management of serum cholesterol levels and thus, ones risk
of contracting CVD (WHO, 1982). It has been shown that
milk and especially fermented milks are able to reduce serum
cholesterol levels in animal trials (Beena and Prasad, 1997; Sibel
Akalin et al., 1997). Kefir grains are capable of reducing the
cholesterol levels of milk through the fermentation process and
have been shown to reduce the levels of cholesterol present by
between 41 and 84% after 24 h fermentation and a further 48 h
of storage (Vujicˇic´, 1992). While cholesterol reduction varied
from one grain to another, these differences did not reflect the
country of origin of the grain; Yugoslavian grains had both the
highest and lowest levels of cholesterol reduction. Single kefir
isolates have also been shown to assimilate cholesterol, with K.
marxianus being one of the more effective. When K. marxianus
strains K1 and M3 were inoculated in broth supplemented
with cholesterol for 20 h, cholesterol levels decreased 70–99%
(Liu et al., 2012). These same strains of K. marxianus showed
significant levels of bile salt hydrolase (BSH) activity which
were proportional to the rate of cholesterol lowering (Liu et al.,
2012). BSH deconjugates bile acids and, as deconjugated bile
salts is less soluble and less efficiently reabsorbed from the
intestinal lumen, this leads to increased bile salt excretion in the
faces (Zhuang et al., 2012). BSH deconjugation contributes to
cholesterol lowering abilities of kefir as cholesterol is utilized in
bile acid synthesis.
Cholesterol lowering properties of kefir have been validated
in animal models. In a study using male golden Syrian hamsters
fed cholesterol free or cholesterol enriched diet, both milk
kefir and soyamilk kefir reduced serum triacylglycerol and total
cholesterol while improving the atherogenic index (i.e., ratio
of non-HDL-cholesterol to HDL-cholesterol). The cholesterol
lowering effect was independent of whether the hamsters were fed
the cholesterol free or cholesterol enriched diet (Liu et al., 2006a)
indicating that kefir feeding altered endogenous cholesterol
metabolism. Concentrations of cholesterol in the liver were also
observed to decrease in both milk kefir and soyamilk kefir
fed hamsters, and the secretion levels of fecal bile acid and
cholesterol significantly increased for both groups. The increase
in fecal bile acid is likely a result of the deconjugation of bile
acid by microbes present in the kefir, while the higher levels
of cholesterol secretion were likely due to the inhibition of
cholesterol absorption in the small intestine due to the binding
and assimilation of cholesterol by these same microbes (Xiao
et al., 2003).
Lactobacillus plantarum MA2 isolated from kefir has also
shown hypocholesterolemic activity in male Sprague-Dawley
(SD) rats fed a high cholesterol diet. Rats fed a diet
supplemented with this organism had significantly lower
total serum cholesterol, LDL-cholesterol, triglycerides, liver
cholesterol and triglycerides in conjunction with increased
fecal cholesterol secretion (Wang et al., 2009). A similar
study that used a high cholesterol diet supplemented with
L. plantarum strains Lp09 and Lp45 in SD rats found that
these strains had the same effect (Huang et al., 2013a).
Huang et al. (2013b) also found that L. plantarum Lp27 was
able to decrease serum total cholesterol, LDL-cholesterol, and
triglycerides in hypercholesterolemic SD rats that consumed
a diet supplemented with Lp27. A proposed mechanism for
decreased serum cholesterol is the inhibition of cholesterol
absorption. The Niemann-Pick C1-like 1 (NPC1L1) gene, which
plays a critical role in the absoption of cholesterol (Altmann
et al., 2004), is down-regulated in rats fed Lp27 and in in vitro
tests with Caco-2 cells (Huang et al., 2013b). Zheng et al.
(2013) found that L. acidophilus LA15, L. plantarum B23, and
L. kefiri D17 were all able to lower serum total cholesterol,
LDL, and triglyceride levels in SD rats fed a high cholesterol
diet. The three strains also increased fecal cholesterol and bile
acid secretion (Zheng et al., 2013). K. marxianus YIT 8292 was
also shown to decrease plasma and liver cholesterol levels in
addition to increasing fecal sterol and bile acid excretion and the
concentration of short chain fatty acids in the cecum (Yoshida
et al., 2005), indicating that both bacteria and yeast can contribute
to this characteristic. This effect was shown to be specific to
α-mannan and β-glucan present in the cell wall of K. marxianus
(Yoshida et al., 2005). In addition to individual microbes in
kefir having an ability to reduce cholesterol, kefiran has also
been shown to improve cholesterol and blood pressure levels.
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In a study using spontaneously hypertensive and stroke prone
(SHRSP/Hos) rats fed a high fat diet, kefiran supplementation
reduced serum total cholesterol, serum LDL-cholesterol, serum
triglycerides, liver cholesterol, and liver triglycerides (Maeda
et al., 2004b), however, the concentrations used for kefiran
supplementation were not discussed. Decreases in the blood
pressure and angiotensin converting enzyme (ACE) activity were
also observed. ACE inhibitory action has been attributed to
commercial kefir made from caprine milk when tested in vitro,
with the mode of action being attributed to two small peptides
released from casein during the fermentation process (Quiros
et al., 2005).
In contrast to these studies, St-Onge et al. (2002) found
that when mildly hypercholesterolemic men consumed kefir
as part of their diet for 4 weeks there was no significant
change to total serum cholesterol, LDL-cholesterol, HDL-
cholesterol, or triglyceride concentrations. They did note an
increase in fecal bacterial counts and short chain fatty acid
levels, including propionic acid. Additionally, a study examining
Wistar rats fed a standard diet supplemented with kefir for
22 days found no significant differences in serum cholesterol
when compared to rats on a control diet (Urdaneta et al.,
2007). While these two studies seem to conflict with other
findings, this may be in large part due to the fact that
different kefir grains were used for each of these studies.
Additionally, the aforementioned Liu et al. (2006a) study
had a timeline of 8 weeks, while St-Onge et al. (2002) and
Urdaneta et al. (2007) had timelines of 4 weeks and 22
days, respectively. It may be significant that, in the study
of hypercholesterolemic men, an increase in fecal propionic
acid was noted. Propionic acid has been shown to inhibit
acetate incorporation in to triacylglycerol and plasma cholesterol
(Wolever et al., 1995). Thus, a hypocholesterolemic effect may
have been observed had the study continued for a longer time
period.
EFFECTS ON THE HOST GUT AND GUT
MICROBIOME
Pathogen Exclusion
One of the main ways through which probiotic-containing
food products can exert beneficial effects is altering the gut
microbiota. This can be done either through the introduction
of new species or strains in to the gastrointestinal tract,
or by promoting the growth of beneficial microbes which
are already present. Some examples are presented here.
In multiple studies, consumption of kefir or kefiran in
an animal model has been associated with an increase
in microbes thought of as beneficial, such as Lactobacillus
and Bifidobacterium, while simultaneously decreasing harmful
microbial species such as Clostridium perfringens (Liu et al.,
2006b; Hamet et al., 2016). Kefir consumption was also able
to reduce the severity of Giardia intestinalis infection in
C57BL/6 mice, with the reported mechanism being through
modulation of the immune system (Correa Franco et al.,
2013). Furthermore, specific strains of Lactobacillus isolated
from kefir have been shown to adhere to Caco-2 cells
and inhibit the adherence of Salmonella typhimurium and
Escherichia coli O157:H7 (Santos et al., 2003; Hugo et al.,
2008; Huang et al., 2013a). The ability of these Lactobacillus
species to bind to Caco-2 cells illustrates a likely mechanism
for the increase in Lactobacillus species observed in the
fecal microbiota of rats fed kefir (Liu et al., 2006b; Carasi
et al., 2015). In an in vivo study where BALB/c mice were
intragastrically challenged with E. coli O157:H7, mice receiving
L. kefiranofaciens M1 prior to E. coli challenge showed reduced
symptoms of infection, including intestinal and renal damage,
bacterial translocation, and Shiga toxin penetration as well as
increased EHEC-specific mucosal IgA responses (Chen et al.,
2013)
Other in vitro work has also shown that lactobacilli isolated
from kefir have the ability to protect Vero cells from type II
Shiga toxin produced by E. coli O157:H7, leading to lower levels
of cell death (Kakisu et al., 2013). Similar effects were apparent
in another study where they observed that kefir fermented milk
inhibited the ability of Bacillus cereus extracellular factors to cause
damage to Caco-2 cells (Kakisu et al., 2007).
As well as regulating microbial composition, kefir can alter the
activity of the microbiota. Certain Bifidobacterium strains have
been shown to exhibit increases in growth rate when cultured
in kefir and changes in gene expression have also been observed
(Serafini et al., 2014). These changes in gene expression resulted
in increased expression levels of multiple genes associated with
pil3, a sortase dependent pilus that has been shown to be
extremely important for interaction with the host endothelial
cells and is especially important for adherence and modulation
of the host inflammatory response (Turroni et al., 2013; Serafini
et al., 2014). While this specific example shows the potential
positive effects kefir can have on existing organisms within the
gut microbiota, it is still unclear as to how this translates to the
complex population of the whole microbiome.
Antibacterial and Antifungal Properties
Kefir, and kefir associated strains, has shown a multitude of
antibacterial and antifungal activities (Table 2). Kefir fermented
milk has been tested in disk diffusion experiments against a
wide range of pathogenic bacterial and fungal species and found
to have antimicrobial activity equal to ampicillin, azithromycin,
ceftriaxone, amoxicillin, and ketoconazole against many of these
species (Cevikbas et al., 1994; Yüksekdag˘ et al., 2004; Rodrigues
et al., 2005; Huseini et al., 2012).
In addition to the antimicrobial effects of kefir fermented
milk as a whole, there are also specific microbes which
exert antimicrobial properties on their own. For instance,
L. plantarum ST8KF produces the bacteriocin ST8KF which
exhibits antimicrobial action against Enterococcus mundtii and
Listeria innocua (Powell et al., 2007). Other kefir-derived
Lactobacillus species such as L. acidophilus and L. kefiranofaciens,
as well as some S. thermophilus strains have shown antimicrobial
activity against a whole range of pathogenic organisms including
E. coli, L. monocytogenes, S. aureus, S. typhimurium, S.
enteritidis, S. flexneri, P. aeruginosa, and Y. enterocolitica
when tested using an agar spot test (Santos et al., 2003;
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TABLE 2 | List of pathogenic organisms that kefir or kefir-associated organisms have demonstrated antimicrobial effects against.
Microbial species Reference
Bacteria
Staphylococcus aureus Cevikbas et al., 1994; Ryan et al., 1996; Yüksekdag˘ et al., 2004; Rodrigues
et al., 2005; Miao et al., 2014; Leite et al., 2015; Zanirati et al., 2015
Pseudomonas aeruginosa Cevikbas et al., 1994; Ryan et al., 1996; Yüksekdag˘ et al., 2004; Rodrigues
et al., 2005; Huseini et al., 2012; Zanirati et al., 2015
Salmonella typhimurium Santos et al., 2003; Rodrigues et al., 2005; Golowczyc et al., 2008; Zanirati
et al., 2015
Escherichia coli Ryan et al., 1996; Santos et al., 2003; Yüksekdag˘ et al., 2004; Rodrigues et al.,
2005; Golowczyc et al., 2008; Leite et al., 2015; Zanirati et al., 2015
Salmonella enteritidis Santos et al., 2003; Miao et al., 2014
Listeria monocytogenes Ryan et al., 1996; Santos et al., 2003; Rodrigues et al., 2005; Likotrafiti et al.,
2015; Leite et al., 2015; Zanirati et al., 2015
Bacillus subtilis Cevikbas et al., 1994; Ryan et al., 1996
Salmonella enterica Golowczyc et al., 2008; Miao et al., 2014; Leite et al., 2015
Enterococcus faecalis Ryan et al., 1996; Zanirati et al., 2015
Shigella flexneri Santos et al., 2003
Clostridium difficile Rea et al., 2007
Klebsiella pneumonia, Proteus vulgaris Cevikbas et al., 1994
Streptococcus pyogenes, Staphylococcus salivarius Rodrigues et al., 2005
Bacillus cereus, Clostridium sporogenes,
C. tyrobutyricum, Enterococcus faecium,
Listeria innocua, Salmonella typhi
Ryan et al., 1996
Salmonella gallinarum, Shigella sonnei Golowczyc et al., 2008
Bacillus thuringiensis, Shigella dysenteriae Miao et al., 2014
Fungus
Candida albicans Rodrigues et al., 2005
Yersinia entocolitica Santos et al., 2003
Aspergillus flavus, A. niger, Rhizopus nigricans, Penicillium
glaucum
Miao et al., 2014
Staphylococcus epidermidis, Candida stellatoidea,
C. tropicalis, C. krusei, Saccharomyces cerevisiae,
Rhodotorula glutinis, Torulopsis glabrata
Cevikbas et al., 1994
Yüksekdag˘ et al., 2004; Golowczyc et al., 2008). Other kefir
lactobacilli have also shown antimicrobial activity in in vitro
tests against S. typhimurium, and E. coli that have already
adhered to Caco-2 cells (Golowczyc et al., 2008). Lacticin
3147 is produced by a strain of L. lactis isolated from kefir
and has an extremely broad range of antimicrobial activity,
affecting B. cereus, B. subtilis, C. sporogenes, C. tyrobutyricum,
Enterococcus faecium, E. faecalis, L. innocua, L. monocytogenes,
S. aureus, and C. difficile (Ryan et al., 1996; Rea et al.,
2007). Another bacteriocin of kefir origin is F1, which is
produced by the Lactobacillus paracasei subsp. tolerans strain
FX-6 source from a Tibetan kefir grain. F1 has been shown
to inhibit a wide range of bacterial and fungal species
including S. aureus, Shigella dysenteriae, and Aspergillus niger
(Miao et al., 2014). L. kefiri B6 isolated from kefir was also
capable of inhibiting and inactivating L. monocytogenes when
in the presence of galactooligosaccharide in vitro, however,
this effect was not observed with E. coli and, in this case,
further investigation of the mechanism of this inactivation
is needed (Likotrafiti et al., 2015). Similarly, Leite et al.
(2015) isolated multiple strains of L. lactis and Lb. paracasei
from kefir capable of producing bacteriocin-like substances
that were inhibitory to E. coli, S. enterica, S. aureus, and
L. monocytogenes, however, more work is needed in order to
better characterize these substances and determine the range
of their antimicrobial activity as well as their novelty. In
a study examining LAB isolated from Brazilian kefir grains,
L. kefiranofaciens 8U showed the ability to inhibit multiple
pathogens including P. aeruginosa, L. monocytogenes, and
E. faecalis in vitro, but again more work is needed in order to
determine the mechanism behind this inhibition (Zanirati et al.,
2015).
ANTITUMOR EFFECTS
Kefir also has significant antitumor activity against multiple
cancer cell types. L. kefiri was shown to increase apoptosis of
multiple drug resistant human myeloid leukemia cells in vitro
through the activation of caspase 3 in a dose dependent
manner (Ghoneum and Gimzewski, 2014). The cell free
fraction of kefir has shown antitumor activity in vitro when
it was observed to have a dose dependent anti-proliferative
effect on the gastric cancer cell line SGC7901 (Gao et al.,
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2013). This study further demonstrated that cell free kefir
was able to induce apoptosis in SGC7901 cells through up
regulation of the bax gene, and apoptosis promoter and anti-
oncogene, and down regulation of the bcl-2 gene, which is
an apoptosis inhibitor and known oncogene (Sorenson, 2004).
In addition to the promotion of cell death in cancerous
cells, antimutagenic effects have been demonstrated in studies
with known carcinogens such as methylmethanosulphate,
methy-lazoxymethanol, sodium azide, aflatoxin B1, and 2-
aminoanthracene as indicated by the Ames test (Guzel-Seydim
et al., 2006).
In mouse models of fusiform cell sarcomas, mice receiving
intraperitoneal kefir had reduced tumor size, with some tumors
completely disappearing over a 20 days treatment period
(Cevikbas et al., 1994). While this is impressive, it has yet to
be determined if these findings can be replicated in the case of
oral consumption. A separate study utilizing a murine breast
cancer model showed that kefir feeding prior to challenge with
the tumor resulted in decreased size and increased apoptosis of
the tumor, and that the levels of IgA+ cells and CD4+ T cells
were also increased (de Moreno de LeBlanc et al., 2007). Mice
with breast cancer tumors fed kefir also showed increased serum
levels of Il-10 and IL-4 (de Moreno de LeBlanc et al., 2006). These
studies both showed increases in immune cell populations and
recruitment, pointing to a possible mechanism for the reduction
of tumor size. These findings are consistent with other studies
that have shown that kefir is able to modulate the immune system
in the gut and show that the immunomodulatory abilities of kefir
may not be limited to the gastrointestinal tract (Thoreux and
Schmucker, 2001; Vinderola et al., 2005; Correa Franco et al.,
2013).
WOUND HEALING
The antimicrobial properties of kefir may lead to its use for non-
traditional applications. Indeed, when rats bearing open wounds
inoculated with S. aureus were treated with a gel made from kefir
grains, it was found that the wounds healed at a much faster rate
than was observed in control rats that received no treatment or
rats that received a traditional treatment of 5 mg/kg neomycin-
clostebol emulsion (Rodrigues et al., 2005). Gels made from kefir
and kefir grains were found to be more effective at reducing
wound size in P. aeruginosa contaminated third degree burns
than a traditional silver sulfadiazine treatment in a rat model
of burn wounds (Huseini et al., 2012; Rahimzadeh et al., 2014).
Furthermore, a study using a rabbit model for contaminated open
wound also found that gel made from kefir grain resulted in
quicker healing times and quicker clearing of infection (Atalan
et al., 2003).
These decreased healing times are likely due to multiple
factors. One such factor is the ability of kefir to inhibit the growth
of bacterial and fungal cells, thus leading to a cleaner wound, as
shown to be the case in some studies (Atalan et al., 2003; Huseini
et al., 2012). Another possible factor is the ability to modulate the
immune system and recruit immune cells to help with the healing
process.
IMMUNOMODULATORY EFFECTS
One of the major ways probiotic products such as kefir are able
to produce health benefits is through the modulation of the
gastrointestinal immune system. When young rats inoculated
intra-duodenally with cholera toxin (CT) were fed kefir, the levels
of anti-CT IgA in the serum increased as did the secretion levels
of anti-CT IgA in the Peyer’s Patches, the mesenteric lymph
nodes, the spleen, and the intestinal lamina propria compared
to CT alone (Thoreux and Schmucker, 2001). This same effect,
however, was not observed in older mice that underwent the same
treatment, suggesting that whatever mechanism is responsible for
the observed change in the young rats is either no longer present
in the senescent mice or requires a much larger dosage of kefir
in order to activate it. Additional studies in to the mechanism
as well as investigations with middle aged mice are needed to
provide further insight in to this phenomenon. In an infection
of C57BL/6 mice with G. intestinalis, kefir consumption reduced
intensity of infection by mitigating the ability of G. intestinalis
to suppress the mounting of an inflammatory response. This
impact was mediated through increases in the levels of TNF-α
and IFN-γ expression and through higher levels of IgA positive
and RcFcε positive cells (Correa Franco et al., 2013). There
have also been studies showing increases in IgA and IgG+
cells in the small intestine of rats that were fed both regular
and pasteurized kefir, as well as increases in the levels of IL-
4, IL-10, IL-6, and IL-2 positive cells in the lamina propria of
these same rats. Increases were also seen in anti-inflammatory
cytokines such as IL-10, IL-4, and IL-6, all of which promote
a Th2 response (Vinderola et al., 2005). Interestingly, increases
in IFN-γ, TNFα, and IL-12 (all of which are pro-inflammatory
and promote a Th1 response) were observed only in rats fed
pasteurized kefir. The increase in pro-inflammatory cytokines in
the pasteurized kefir groups was likely due to the reduced cell
wall integrity of heat killed cells exposing more inflammatory
microbial products. The fact that pasteurized kefir was able to
elicit an effect shows that the mechanisms behind this immune
modulation are not entirely dependent on live cells, and may be
due to metabolites present in the kefir (Iraporda et al., 2014).
However, it should be noted that in this study live cells had
a generally more substantial impact as live kefir was able to
confer a similar effect at 1/10 the concentration and without
eliciting a pro-inflammatory immune response (Vinderola et al.,
2005).
When fed to mice over 2–7 days, solid fractions of kefir
that contained live bacteria have been shown to increase the
levels of IFN-γ, TNF-α, and IL-6 in peritoneal macrophages
as well as to increase the levels of IL-1α, IL-10, and IL-
6 in adherent cells isolated from the Peyer’s patch of mice
(Vinderola et al., 2006b). IFN-γ and TNF-α increased early
in feeding, however, they quickly decreased back to control
levels by day 7 along with IL-1α while IL-6 and IL-10 levels
remained high through the 7 days feeding period (Vinderola
et al., 2006b). In vitro experiments with lactobacilli isolated
from kefir have shown that they induce higher secretion levels
of IL-1β, IL-6, TNF-α, IL-10, IL-8, and IL-12 in peripheral
blood mononuclear cells and are able to decrease the ccl20
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response in Caco-2 cells to TLR agonists such as bacterial
flagella, with largely different effects being observed for different
strains of lactobacilli tested (Carasi et al., 2015). In general,
strains of L. kefiri that induced lower TNF-α/IL-10 and higher
IL-10/IL-12 ratios showed a much greater decrease in the pro-
inflammatory response of ccl20 to stimulation with bacterial
flagella, indicating the importance of IL-10 in promoting a Th2
response while simultaneously inhibiting the pro-inflammatory
Th1 response. Mice that were fed L. kefiri for a period of
21 days showed altered gene expression profiles in the ileum,
colon, Peyer’s Patches, and mesenteric lymph nodes, with
proinflammatory cytokines such as IFN-γ and IL-23 being down
regulated and IL-10 being up regulated (Carasi et al., 2015). This
further indicates that lactobacilli isolated from kefir have the
ability to supress the production of pro-inflammatory cytokines
while promoting anti-inflammatory cytokine production. L.
kefiranofaciens co-incubation with mouse macrophage cells
decreased the levels of pro-inflammatory cytokines IL-1β, and
IL-12 while simultaneously increasing the level of the anti-
inflammatory cytokine IL-10, which acts to specifically inhibit the
production of IL-12 and IL-1β (Hong et al., 2009). Additionally,
L. kefiranofaciens was able to ameliorate colitis in a DSS induced
mouse model and enhance Th1 responses to TLR agonists
in germ free mice by increasing the production of IFN-γ
and IL-12 upon stimulation (Chen and Chen, 2013). Further
investigation into the mechanisms of protection against colitis
showed that L. kefiranofaciens M1 decreased the production of
pro-inflammatory cytokines IL-1β and TNF-α, while increasing
the production of IL-10 in vivo (Chen et al., 2012). This effect
was also TLR-2 dependent as L. kefiranofaciens M1 was unable
to improve DSS colitis in TLR-2 knockout mice (Chen et al.,
2012).
The cell free fraction of kefir is also capable of modulating
the immune system, and has been shown to modulate innate
immune responses in vitro by lowering the activation of Caco-
2-ccl20:luc cells that had been stimulated by Salmonella flagellar
protein FliC, IL-1β, or TNF-α (Iraporda et al., 2014). One of
the likely mechanisms was revealed when it was found that
a 100 mM lactic acid solution at pH 7 was able to elicit a
comparable level of immune modulation in FliC stimulated
cells when preincubated with the solution (Iraporda et al.,
2014). The lactic acid solution was also found to lower the
level of NFκ-B activation in Caco-2 cells stimulated with FliC
and was even able to down regulate the expression of pro-
inflammatory cytokines ccl20, IL-8, CXCL 2, and CXCL 10
without affecting genes involved in the normal function of
enterocytes (Iraporda et al., 2014). These results indicate just how
important the metabolites produced during fermentation are to
the ability of kefir to elicit beneficial responses or effects in the
host.
In general studies using whole kefir, kefir fractions, or
organisms isolated from kefir found that whether tested in vitro
or in vivo, the result was a shift from a Th1 immune response
to a Th2 response as well as increases in the levels of IgA
present (Thoreux and Schmucker, 2001; Vinderola et al., 2005,
2006b; Hong et al., 2009; Carasi et al., 2015). The only study
which seems to show a consistently increased Th1 response was
conducted with germ free mice, while all other studies used
conventional mice or rats (Chen and Chen, 2013). This may
account for the difference in findings as it is quite possible that
the observations from the germ free mice had more to do with
the introduction of a bacterial population to the gut than it did
with the specific bacterial species that comprised that population.
The fact that most studies also observed increases in some pro-
inflammatory cytokines such as TNF-α, IFN-γ, or IL-12 may
be explained by an initial reaction of the immune system to
common TLR agonists present, which was ultimately supressed
following further interaction with the immune cells of the GI
tract.
ANTI-ALLERGENIC EFFECTS
Allergic diseases have been on the rise in the developed
world for decades, leading to higher incidences of conditions
such as asthma and food allergy (Yazdanbakhsh et al., 2002).
Many allergies, especially those related to food, are developed
early in life, with the majority of food allergies developing
within the first 2 years of life (Wood, 2003). Although
most food allergies developed early in life do not persist,
some can become lifelong conditions (Wood, 2003). Recent
work has shown that an increasingly important factor in
determining if a child develops allergic disease, be it food
allergy or asthma, is the level of complexity and the specific
organisms present in the gut microbiota (Kirjavainen et al.,
2002; Sjogren et al., 2009; Azad et al., 2013; West, 2014).
Higher levels of Bifidobacterium and group 1 lactobacilli
(obligate heterofermentative lactobacilli such as L. acidophilus,
L. delbrueckii, and L. helveticus) in the gut of infants have
been associated with a lower incidence of allergic disease
later in life (Sjogren et al., 2009), and both kefir and
kefiran have been observed to exert these effects on the gut
microbiota in animal trials (Liu et al., 2006b; Hamet et al.,
2016). Supplementation with Bifidobacterium has been shown
to influence the intestinal microbiota of weaning infants by
reducing levels of Bacteroides and has been associated with lower
incidence of food allergy (Kirjavainen et al., 2002). Studies with
antibiotics in the early life period have also highlighted the
importance of appropriate microbial stimulation of the immune
system for protection against asthma development (Russell et al.,
2012).
One of the main mechanisms behind food allergy is an
imbalance in the Th1/Th2 cell ratio, leading to a heightened IgE
response (Tanabe, 2008). Studies of in vitro reactions of human
monocytes with a probiotic made up of multiple LAB showed
that exposure to these LAB resulted in a much higher IFN-γ/IL-
4 ratio, similar to what would be seen during a Th1 response
(Tsai et al., 2012). In addition to the in vitro studies carried out,
Tsai et al. (2012) found that both total IgE and OVA-specific IgE
were significantly lower in mice that had been sensitized to OVA
(ovalbumin) and then fed a LAB mixture than in control mice
which had also been sensitized to OVA but did not receive any
LAB mixture. Studies such as this indicate that kefir may help
relieve some allergy symptoms.
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In a study utilizing an ovalbumin sensitization mouse asthma
model, it was found that mice receiving intra-gastric kefir showed
lower levels of airway hyper-responsiveness (AHR) than control
mice, and, impressively, had lower levels of AHR than the
positive control group receiving an anti-asthma drug (Lee et al.,
2007). This same study found that mice receiving kefir exhibited
significantly lower levels of eosinophil infiltration in the lung
tissue as well as in the brochoalveolar lavage fluid (BALF). These
mice also showed lower levels of IgE, IL-4, and IL-13 in the
BALF, all of which are associated with the Th2 response which is
responsible for allergic reaction (Lee et al., 2007). It has also been
found that oral feeding of kefir in OVA sensitized mice resulted
in significantly lower levels of anti-OVA serum IgE and IgG1
antibodies than those found in mice given water or unfermented
milk (Liu et al., 2006b). Studies examining the in vitro effect of
heat-killed lactobacilli isolated from kefir on mouse peritoneal
macrophages showed that even after being heat-inactivated, the
lactobacilli were able to induce the expression of Th1 cytokines
such as IFN-γ, TNF-α, IL-12, and IL-1β (Hong et al., 2010).
These same heat-inactivated lactobacilli also reduced the levels
of anti-OVA IgE in the serum when fed orally to OVA sensitized
mice, while increasing the expression of IL-12 and decreasing the
expression of IL-5 in splenocytes. An increase in the levels of
regulatory T-cells was also detected in these mice (Hong et al.,
2010). In a study of OVA sensitized mice fed with heat-inactivated
strain M1 of L. kefiranofaciens, the inactivated M1 was able to
decrease levels of pro-inflammatory and Th2 cytokines such as
IL-4, IL-6, IL13, and ccl20 in both the splenocytes and BALF
of the mice while decreasing OVA-specific IgE and the Th17
associated cytokine IL-17, both of which are strongly associated
with an asthmatic response. The M1 treatment was also able to
increase the levels of regulatory T cells present (Hong et al., 2011).
While all of these studies reveal a consistent pattern, it is
interesting to note that many of the cytokine profiles are in stark
contrast to those found in studies without antigen sensitization
or challenge. This highlights both the complexity of the immune
system and the need for a balance between the different possible
reactions such as the Th1 and Th2 responses. The fact that
kefir can induce shifts in the immune system in both directions
is promising as it may mean that the organisms in kefir are
capable of regulating this balance in the immune system. This
may be in part due to the increased number of regulatory
T-cells observed in some of these studies, as regulatory T-cells
play an important role in maintaining tolerance and supressing
unnecessary inflammatory immune responses (Sakaguchi, 2011).
HEALTH BENEFITS OF YEAST IN KEFIR
As noted above, one unique characteristic of traditionally
produced kefir relative to many other commercially produced
fermented dairy products is the presence of a large population
of yeast in both the kefir grain and in the fermented milk (Marsh
et al., 2013). Although the majority of commercialized probiotic
microbes are bacteria such as lactobacilli and bifidobacteria, there
are some yeast species and strains that have been recognized
to have probiotic properties, such as Saccharomyces boulardii
(Corthier et al., 1986; Czerucka et al., 2007). S. boulardii has
been shown to improve the symptoms of Clostridium difficile
associated diarrhea as well as reduce inflammation and alter the
immune state and reactions in the gut, leading to its adoption as
a treatment for C. difficile diarrhea (Buts et al., 1994; Castagliuolo
et al., 1999; Kotowska et al., 2005; Villarruel et al., 2007).
Some yeasts from kefir have also shown immunomodulatory
activities. For example K. marxianus B0399 has been shown to
have the ability to adhere to Caco-2 cells (Maccaferri et al., 2012).
When co-incubated with lipopolysaccharide (LPS) stimulated
Caco-2 cells, a significant decrease in the secretion of IL-10,
IL-12, IL-8, and IFN- γ was observed (Maccaferri et al., 2012).
Additionally, K. marxianus B0399 elicited a decrease in the
secretion of pro-inflammatory cytokines TNF-α, IL-6, and MIP-
1α when co-incubated with PBMCs that had been stimulated
with LPS (Maccaferri et al., 2012). This same study showed that
in an in vitro colonic model system, K. marxianus was able
to stably form a population in the model while simultaneously
enhancing the levels of Bifidobacterium. Increases in the levels
of the short chain fatty acids acetate and propionate were also
observed. Utilizing a Caco-2 cell line with a ccl20 reporter gene,
Romanin et al. (2010) were able to show that multiple yeast
strains of S. cerevisiae (CIDCA 81109, 81106, 8112, 9127, 9123,
9136, 9133, 9124, 81103, 9132, 81108, 81102, 8175, and 8111),
K. marxianus (CIDCA 81111, 8116, 8118, 81105, 8153, 8154,
8113, 81104, and 9121), and Issatchenkia spp. (CIDCA 9131)
were able to inhibit the expression of the ccl20 reporter when
incubated with the cells prior to stimulation with Salmonella
flagellar protein FliC. From these yeasts, K. marxianus CIDCA
8154 was selected for further testing and showed the ability to
inhibit the levels of ccl20 expression in Caco-2 cells regardless of
whether the stimulation came from FliC, IL-1β, or TNF-α. The
strain also inhibited the expression of IL-8 and MIP-2α in HT-29
cells and inhibited ccl20 expression in a mouse ligated intestinal
loop model when administered prior to stimulation with FliC
(Romanin et al., 2010). Yeasts isolated from kefir have also shown
the ability to improve the probiotic properties of bacterial species
by improving the viability of these bacterial strains over time in
simulated gastric and intestinal juice, and through improving the
adhesion of LAB to Caco-2 cells in an in vitro model. This effect is
likely due to the co-aggregation of the two microbial species (Xie
et al., 2012).
KEFIRAN AND THE CELL FREE
FRACTION OF KEFIR
In addition to the microbial populations present in kefir and
other fermented probiotics, there are also fermentation products
and other by-products of the metabolism of these microbes
that possess bioactivity. Some of these by-products may have a
profound effect on the host without the presence of the microbial
population. Such a by-product is kefiran, the exopolysaccharide
produced by L. kefiranofaciens during fermentation (Maeda
et al., 2004b; Vinderola et al., 2006a). Mice fed kefiran dissolved
in drinking water showed increases in the levels of IgA+ B
cells, as well as increases in IL-6, IL-10, and IL-12 in the
Frontiers in Microbiology | www.frontiersin.org 12 May 2016 | Volume 7 | Article 647
fmicb-07-00647 May 2, 2016 Time: 18:47 # 13
Bourrie et al. Health Promoting Characteristics of Kefir
lamina propria of the small intestine after 7 days of feeding
(Vinderola et al., 2006a). In a murine model of asthma using
OVA sensitization, kefiran introduced intra-gastrically 1 h prior
to challenge reduced levels of the Th2 cytokines IL-4 and IL-
5 and lowered AHR when compared to OVA challenged mice
that did not receive kefiran (Kwon et al., 2008). After the
same period the study showed increases in serum levels of
IL-4, IL-6, IL-10, and IFN-γ (Kwon et al., 2008). Addition
of kefiran to a co-incubation of B. cereus culture supernatant
and Caco-2 cell monolayer resulted in reduced cell detachment
and greater mitochondrial activity, as well as negated the
haemolytic effect of the B. cereus culture supernatant on human
red blood cells (Medrano et al., 2008). Genetically diabetic
(KKAy) mice fed kefiran were found to have decreasing levels
of blood glucose throughout a 30 days examination while a
control group was found to have constantly increasing and
generally higher levels of blood glucose throughout the same
timeline (Maeda et al., 2004a). Using SD rats as a model for
constipation, it was also found that kefiran significantly improved
the symptoms of constipation over the control group (Maeda
et al., 2004a).
A water-soluble polysaccharide isolated from kefir grain
(KGF-C) was shown to improve humoral immune response in
mice against Sheep Red Blood Cells (SRBC). The levels of anti-
SRBC cells isolated from the spleen of mice immunized with
SRBC while being intubated with KGF-C was significantly higher
than in control mice 4 days post immunization (Murofushi
et al., 1986). However, this effect was not seen in nu/nu
mice (no thymus or T cell population) immunized with
SRBC, or in conventional mice immunized with thymus-
independent antigens, indicating that the mechanism of action
is likely through the T cell population (Murofushi et al., 1986).
Sphingomyelin isolated from kefir has been shown to increase
IFN-β secretion in human MG-63 cells when compared to
commercial sphingomyelin and sphingosine (Osada et al., 1993).
Kefir cell-free supernatant (KCFS) has been shown to increase
the levels of IFN-β, IL-6, IL-12, and TNF-α secreted by RAW
264.7 cells through a TLR2 dependent mechanism (Hong et al.,
2009). Cell-free fractions of kefir have also been shown to increase
the levels of these cytokines in peritoneal macrophages and
adherent cells from the Peyer’s patches of mice (Vinderola et al.,
2006b). In addition, KCFSs were found to have a significant
impact on tumor size, apoptosis, and immune recruitment in a
murine breast cancer model, resulting in increased apoptosis of
tumor cells and increases in the CD4+ T cell population (de
Moreno de LeBlanc et al., 2007). In in vitro studies utilizing
human T-lymphotropic virus 1 (HTLV-1) positive HuT-102
Malignant T lymphocytes as a model for T cell leukemia, the
KCFS was found to inhibit proliferation by up to 98% while
simultaneously decreasing the transcriptional levels of TGF-
α. These effects have also been observed in HTLV-1 negative
malignant T cells with the same decrease in TGF-α transcription
being observed (Rizk et al., 2009; Maalouf et al., 2011). In addition
to anti-proliferative effects, KCFS was found to induce apoptosis
in both HTLV-1 positive and negative malignant T cells through
the up regulation of bax and down regulation of bcl-2 in a dose
dependent manner (Rizk et al., 2013).
CONCLUSION
The purpose of this review has been to collate and summarize
that which is known about the microbial composition of
kefir and how this composition plays a role in the health
benefits associated with kefir consumption. Kefir is a dynamic
fermented dairy product with many different factors affecting
the benefits associated with its consumption. These factors
include the variable yeast and bacterial species present, as well
as metabolites such as kefiran and other exopolysaccharides.
While kefir has been associated with health benefits for 100s
of years, the exact form of these benefits has, until recently,
not been studied. The use of animal models and other
in vitro analyses has allowed for the elucidation of how kefir
positively impacts host health. Whole kefir, as well as specific
fractions and individual organisms isolated from kefir, provide
a multitude of positive effects when consumed. These range
from improved cholesterol metabolism and wound healing,
to the modulation of the immune system and microbiome,
and even the potential alleviation of allergies and cancers.
Further studies into the mechanisms behind these effects
will allow scientists to better understand exactly how kefir
and other fermented dairy products confer these benefits
as well as how to harness these traits outside of kefir
itself.
The wide range of potential health promoting effects of
kefir could lead to a further expansion on the popularity
of both traditional fermented kefir and products that are
manufactured with kefir fractions or organisms. In order
to fully exploit the beneficial characteristics of kefir, a
more in-depth understanding of the composition of kefir is
critical. With advances in metagenomic analysis through the
development of high-throughput sequencing technology, this
is a very realistic prospect. Armed with this knowledge, it
should be possible to more readily isolate and examine the
phenotypic characteristics of individual organisms present
in a kefir blend while also providing a greater insight into
the evolution of these organisms and how they became
specialized to the kefir ecosystem. The additional knowledge
gained can also provide crucial information relating to the
mechanisms and exact agents responsible for beneficial
effects that have been attributed to kefir (Atalan et al., 2003;
Rodrigues et al., 2005; Huseini et al., 2012; Rahimzadeh et al.,
2014).
The need for further research does not only apply to the
mechanisms by which kefir consumption exerts these effects
but also which organisms or parts of kefir are responsible for
each benefit. By determining which organisms and metabolites
are essential for each process, the possibility arises for the
commercial manufacturing of kefir that is specifically designed
to create the most profound effect in those that consume it. As
it stands currently, the highly variable nature of the organisms
and metabolites present in traditional kefir requires health claims
to be verified individually in each grain and kefir beverage. The
ability to combine the best possible strains of the best organisms
from multiple sources of kefir would create the potential for
greater benefits than have been previously observed, with a
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measure of control over these effects that has not been possible in
traditional kefir.
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